Prostate-Specific Antigen (PSA) and Its Association with Cardiovascular Disease Risk in US Men: A Population-Based Study

Zhi-huang Chen, Yi-jiang Liu, Rui Li, Zhan Wang, Jialin Chen, Di Xiao, Shuyan Jiang, Lin-xi Xu, Xin Chen, Jiawei Zhuang, Jiacheng Xu, Zhonggui ShanResearch Square 2024 · DOI

TL;DR

This study identifies a significant association between free Prostate-Specific Antigen (fPSA) levels and the prevalence of cardiovascular disease (CVD) in U.S. men over 40. Analyzing a decade of national health data, researchers found that men with the highest fPSA levels were over 2.5 times more likely to have a history of heart disease, suggesting that this common prostate health marker might also serve as a "red flag" for systemic cardiovascular health.

What Problem Does This Paper Address?

Cardiovascular disease remains the leading cause of mortality globally, yet current screening tools like the Framingham risk score have known limitations. Researchers are constantly searching for new biomarkers that can improve early detection.

While Prostate-Specific Antigen (PSA) is a household name in the context of prostate cancer screening, emerging evidence has hinted at a deeper connection between prostate health and heart health. Previous small-scale studies observed PSA spikes following heart attacks or in patients with coronary artery disease, but these findings were often inconsistent. This paper addresses the lack of large-scale, representative evidence by investigating whether PSA levels—specifically total PSA (tPSA), free PSA (fPSA), and the percentage of free PSA (%fPSA)—correlate with CVD risk in the general male population.

Methods

The researchers conducted a cross-sectional study using multivariate logistic regression to calculate odds ratios (OR). They employed two primary models:

  • Model 1: An unadjusted model looking strictly at the PSA-CVD relationship.
  • Model 2: A fully adjusted model that controlled for a wide array of confounding factors, including race/ethnicity, BMI, waist circumference, smoking status, alcohol intake, education, marital status, poverty-to-income ratio (PIR), and diabetes status.

A key part of their approach was quartile analysis. They divided the participant pool into four groups (quartiles) based on their fPSA levels to see if the risk of CVD increased progressively with higher concentrations of the antigen.

Datasets

The study utilized data from the National Health and Nutrition Examination Survey (NHANES), a major program of studies designed to assess the health and nutritional status of adults and children in the United States.

  • Timeframe: Data was extracted from cycles spanning 2001 to 2010.
  • Sample Size: Out of an initial pool of 52,195 individuals, the researchers narrowed the focus to a final analytic sample of 6,199 men aged 40 and older who had complete data for both PSA levels and cardiovascular conditions.

Key Insights and Ideas

  • fPSA is a Stronger Signal than tPSA: While total PSA is the standard clinical metric for prostate screening, this study found that free PSA (the portion of PSA not bound to proteins in the blood) was a much more sensitive indicator of cardiovascular history.
  • The Inflammation Hypothesis: The authors suggest that elevated fPSA might reflect chronic systemic inflammation. Since inflammation is a shared driver for both benign prostatic conditions and atherosclerosis, fPSA may be acting as a proxy for the inflammatory state of the cardiovascular system.
  • The Testosterone Connection: fPSA secretion is regulated by testosterone. Given that higher testosterone levels have been linked in some studies to increased cardiovascular risk, fPSA might be capturing a hormonal interplay that affects heart health.
  • Consistency Across Covariates: Even after adjusting for traditional heavy-hitters like smoking, diabetes, and high BMI, the link between fPSA and CVD remained robust, suggesting it provides independent predictive value.

Key Results

  • Significant Risk Increase: In the fully adjusted model, men in the highest quartile of fPSA (Q4) had an Odds Ratio of 2.55 (95% CI: 1.98–3.29) for CVD compared to those in the lowest quartile (Q1).
  • Comparative Effects: The association was much weaker for total PSA (OR: 1.08) and non-significant for the percentage of free PSA (%fPSA, OR: 1.01).
  • Baseline Differences: Participants with CVD were generally older, had higher waist circumferences, and were more likely to be former smokers or diabetic—all of which align with established medical knowledge, lending further credibility to the study’s data.

Limitations and Future Work

The authors acknowledge several critical limitations:

  • Causality: Because this is a cross-sectional study, it can only show an association, not a cause-and-effect relationship. It is unclear if high fPSA leads to CVD or if the conditions simply co-occur.
  • Self-Reporting: CVD data was based on self-reported physician diagnoses, which introduces the possibility of recall bias.
  • Unmeasured Variables: While many factors were controlled for, others—like specific physical activity levels or undiagnosed prostate diseases—could still influence the results.
  • Future Directions: The researchers call for longitudinal studies (tracking participants over time) and experimental validations to uncover the exact biological mechanisms linking prostate antigens to heart health.

Summary updated

Abstract

<title>Abstract</title> Background This study aims to examine the associations of total PSA (tPSA), free PSA (fPSA), and PSA ratio with CVD risk in the adult male population of the United States. Methods In this study, we utilized data from the National Health and Nutrition Examination Survey (NHANES) database with cardiovascular condition,PSA levels and confounding factor information spanning 2001 to 2010. We tabulated the selected data to compare the baseline characteristics of participants.Using a multivariate logistic regression model, we calculated odds ratios (OR) and 95% confidence intervals (95% CI) to assess the potential correlation between total PSA (tPSA), free PSA (fPSA), and the PSA ratio with the odds of CVD and revealed that fPSA was the most significantly related. Subsequently, we divided fPSA into quartiles to further explore the differences in risk association among the different intervals. Additionally we applied forest plots to display the effects of covariates in this risk relation. Two-sided p-tests derived from Wald tests were applied to verify the significance of the results. Results Higher fPSA levels were significantly associated with an elevated risk of CVD in each model(Model1: OR:1.90;95%CI: 1.48–2.46; P &lt; 0.001 ;Model2: OR:1.89;95%CI: 1.47–2.42; P &lt; 0.001 ;Model3:OR:1.71;95%CI: 1.33–2.20; P &lt; 0.001). The multivariable OR for the highest versus lowest quartile of fPSA after fully adjusted was 2.55 (95% CI: 1.98–3.29; P-trend &lt; 0.001). Similar but weaker associations were observed for tPSA and PSA ratio. In the fully adjusted model of tPSA, the OR was 1.08 (95% CI: 1.03–1.12; P &lt; 0.001), and for PSA ratio, the OR was 1.01 (95% CI: 1.00-1.01; P = 0.11). Conclusions Our study suggests that elevated fPSA levels may be associated with a higher prevalence of CVD. This analysis offers a novel perspective on the complex relationship between PSA and CVD. Further research is warranted to elucidate the potential mechanisms underlying this association in this filed.
BibTeX
@inproceedings{chen2024prostate,
  author = {Zhi-huang Chen and Yi-jiang Liu and Rui Li and Zhan Wang and Jialin Chen and Li Li and Di Xiao and Shuyan Jiang and Lin-xi Xu and Xin Chen and Jiawei Zhuang and Jiacheng Xu and Zhonggui Shan},
  title = {{Prostate-Specific Antigen (PSA) and Its Association with Cardiovascular Disease Risk in US Men: A Population-Based Study}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-4859544/v1},
}
Figure